A double-blind study comparing paroxetine
and maprotiline in depressed outpatients

Szegedi A, Wetzel H, Angersbach D, Dunbar GC,
Schwarze H, Philipp M, Benkert O
Department of Psychiatry,
University of Mainz, Germany.
Pharmacopsychiatry 1997 May; 30(3):97-105


A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comprised rating of the HAMD-17, MADRS, BRMS, RDS, HAMA, CAS, and CGI scales and registration of adverse events by non-leading questions. An intention-to-treat and a completer analysis were performed. Response was defined as a HAMD-17 reduction of > or = 50% or a HAMD-17 score of < or = 9 at the end of the study or at dropout. The treatment groups were comparable according to demographic data. Overall evaluation indicated equieffective and good antidepressant and anxiety-reducing properties for paroxetine and maprotiline. No persistent significant differences between treatment groups were observed on any assessment instrument. There was no difference in the frequency of observed side-effects, but side-effect profiles were markedly different, as maprotiline patients had more anticholinergic and paroxetine patients more SSRI-typical side-effects.
Dumb drugs
Paroxetine: review
Paroxetine: update
Stopping paroxetine
Antidepressant toxicity
Paroxetine in psychiatry
Maprotiline versus mianserin
Maprotiline versus amitriptiline
Maprotiline versus fluvoxamine
Maprotiline versus moclobemide
Paroxetine v escitalopram (Lexapro)
Psychopharmacology of mood and anxiety disorders

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family